ANA773 - Oncology
During the last decade, significant advances have been made in the use of immunotherapeutic agents for the treatment of cancer. This success is due in part to the scientific community's increased understanding of how the immune system responds to extrinsic and intrinsic biological threats and in part to a greater facility in selectively enhancing immune response in a controlled and beneficial way. The immune system consists of two complex and interrelated components, the innate and adaptive systems.
Activation of toll-like receptors (TLRs) triggers the innate system, which is typically the first line of defense against bacterial and viral infections. The innate system also alerts the adaptive system to respond to any repeated threats. With ANA773, we are seeking to harness the pharmacological response triggered by TLR7 activation to control cancer.
We are currently conducting a Phase I clinical trial of ANA773 in patients with advanced cancer. In order to focus our resources on ANA598, we recently elected to stop enrolling new patients in this study. We plan for currently enrolled patients to continue to receive ANA773 until disease progression is observed and to conclude the trial once all patients reach this point.
Last Updated 8/4/2009
This description contains certain forward-looking statements within the meaning of the Federal securities laws. Our results could vary, perhaps materially, from our projections or expectations. Please see our SEC filings, including our most recent 10-Q, for a discussion of the risk factors that could affect our business.
ANA773 - Oncology